A new diagnostic technology utilizing non-invasive precision medicine technology to improve patient outcomes and reduce healthcare costs.
NuView is using breakthrough precision technology that will distinguish malignant from benign lesions non-invasively in three areas of cancer care. This will change the way many types of cancer are diagnosed and treated using precision medicine technology. Diagnosing and treating cancer with a targeted, specific approach to the disease will help to increase positive patient outcomes and reduced biopsies, while also driving down costs incurred by patients, healthcare providers, and third-party insurance payers.
VPAC1 biomarkers are expressed on cell surfaces in high densities at the onset of oncogenesis. When VPAC1 receptors are targeted, cancer can be diagnosed early, but specifically, allowing physicians to distinguish malignant from benign lesions. NuView’s NV-VPAC1 technology works as a Positron Emission Tomography (PET) imaging agent for the in vivo diagnosis of breast and prostate cancer by combining an NV-VPAC1 peptide with a medical imaging isotope, illuminating cancerous VPAC1 biomarkers for detection and removal.
NuView Life Sciences is focused on creating precision cancer diagnostics and therapeutics to improve patient outcomes while reducing healthcare costs through the development and clinical application of its exclusive peptide analog technology, NV-VPAC1TM.